Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Emerging Therapies in CLL in the Era of Precision Medicine

Cancers(2023)10.3390/cancers15051583Source: DataRank Database

Emerging Therapies in CLL in the Era of Precision Medicine is a research paper published in Cancers (2023). On theSindex it has a DataRank of 0. It has been cited 35 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access35 citations

Download PDF

Cite:

Linked data & code

gen nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 5.64)OA: goldTopics (37)IDs (PubMed, PMC, OpenAlex)Annotations (3)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (2)

Lili Wang ORCID,Prajish Iyer ORCID

Live enrichment

PubMed:36900373 PMC:PMC10000606 OpenAlex:https://openalex.org/W4323314897

National Institutes of Health (NCI)

Grant: R01CA216273

National Institutes of Health (NCI)

Grant: R01CA21623

National Institutes of Health

Grant: 3R01HD021623-02S1

EMBRYO ASSESSMENT BY MEASURING LUTEOTROPIC CAPABILITIES

National Institutes of Health

Grant: 5R01CA216273-04

(PQ8) Genetically faithful murine models for studying disease progression in chronic lymphocytic leukemia

FWCI

5.64

Citation Percentile

1.0%

Citation Trend

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://www.mdpi.com/2072-6694/15/5/1583/pdf?version=1677837096

publisherhttps://www.mdpi.com/2072-6694/15/5/1583/pdf?version=1677837096

publisherhttps://www.mdpi.com/2072-6694/15/5/1583/pdf

journalhttps://doi.org/10.3390/cancers15051583

repositoryhttps://pubmed.ncbi.nlm.nih.gov/36900373

Fields of Study

Chronic Lymphocytic Leukemia ResearchImmunodeficiency and Autoimmune DisordersAcute Lymphoblastic Leukemia research03 medical and health sciences0302 clinical medicine

Keywords

RituximabMedicineBruton's tyrosine kinaseChimeric antigen receptorIbrutinibClinical trialFludarabineDiseaseChronic lymphocytic leukemiaPTENBioinformaticsImmunologyOncologyImmunotherapyPI3K/AKT/mTOR pathwayImmune systemCyclophosphamideTyrosine kinaseInternal medicineLeukemiaBiologyLymphomaGeneticsChemotherapySignal transductionMetabolismSplicingTranscriptomeCllEmerging TherapiesWhole-exomeReview

Sustainable Development Goals

SDG 0: Good health and well-being

Emerging Therapies in CLL in the Era of Precision Medicine

FAIR Checklist

Authors (2)

Funding (4 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)